Stockscreener 앱 받기
33.52
2.27%
0.745
전일 마감가:
$32.78
열려 있는:
$33.09
하루 거래량:
1.51M
Relative Volume:
1.02
시가총액:
$3.23B
수익:
$610.16M
순이익/손실:
$-532.93M
주가수익비율:
-6.0638
EPS:
-5.5287
순현금흐름:
$-442.30M
1주 성능:
+2.12%
1개월 성능:
-0.01%
6개월 성능:
-5.99%
1년 성능:
-28.85%
1일 변동 폭
$32.06
$33.59
1주일 범위
$31.00
$34.21
52주 변동 폭
$25.81
$50.00
울트라제닉스 파마슈티컬 Stock (RARE) Company Profile
명칭
Ultragenyx Pharmaceutical Inc
전화
415-483-8800
주소
60 LEVERONI COURT, NOVATO, CA
RARE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
33.52 | 3.16B | 610.16M | -532.93M | -442.30M | -5.5287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | William Blair | Outperform |
| 2024-06-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-04-22 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-06-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-12-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-03 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-08-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-03-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 개시 | H.C. Wainwright | Buy |
| 2021-08-19 | 개시 | UBS | Sell |
| 2021-07-15 | 개시 | Guggenheim | Neutral |
| 2021-06-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-05-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-05-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-02 | 재개 | Stifel | Buy |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-11-24 | 재개 | Evercore ISI | In-line |
| 2020-11-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2019-08-02 | 재개 | Wedbush | Outperform |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 개시 | Goldman | Neutral |
| 2018-04-18 | 업그레이드 | SunTrust | Hold → Buy |
| 2018-03-22 | 재개 | Piper Jaffray | Overweight |
| 2018-02-21 | 재확인 | Stifel | Buy |
| 2018-01-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 개시 | Credit Suisse | Outperform |
| 2017-12-05 | 재확인 | Barclays | Equal Weight |
| 2017-12-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-09-14 | 업그레이드 | Wedbush | Neutral → Outperform |
모두보기
울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스
Barclays Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $3.28 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. $RARE Shares Acquired by Geode Capital Management LLC - MarketBeat
Barclays Maintains Ultragenyx Pharmaceutical (RARE) Overweight Recommendation - Nasdaq
Ultragenyx to Participate in Investor Conferences in December - Caledonian Record
Ultragenyx (NASDAQ: RARE) to join Citi, Evercore healthcare investor conferences - Stock Titan
RARE: Barclays Lowers Price Target Amid Maintaining Overweight R - GuruFocus
Connor Clark & Lunn Investment Management Ltd. Lowers Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ultragenyx Pharma stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Australia
Is Ultragenyx Pharmaceutical Inc. (UP0) stock a defensive play amid uncertaintyPortfolio Update Report & AI Enhanced Execution Alerts - newser.com
Ultragenyx And Mereo BioPharma: Considering Their Brittle Bone Disease Phase 3 Trials' Prospect - Seeking Alpha
Will Ultragenyx Pharmaceutical Inc. stock reach all time highs in 20252025 AllTime Highs & Growth Focused Entry Reports - newser.com
Can Ultragenyx Pharmaceutical Inc. stock maintain operating margins2025 EndofYear Setup & Verified Chart Pattern Signals - newser.com
Why Ultragenyx Pharmaceutical Inc. stock remains on watchlistsQuarterly Portfolio Review & AI Powered Trade Plan Recommendations - newser.com
Key metrics from Ultragenyx Pharmaceutical Inc.’s quarterly dataJuly 2025 Big Picture & Low Risk High Win Rate Stock Picks - newser.com
Is Ultragenyx Pharmaceutical Inc. still worth holding after the dipTrade Analysis Summary & Weekly Stock Breakout Alerts - newser.com
OMERS increases stake in Ultragenyx’s rare disease drug revenues - Canadian Lawyer Mag
Is Ultragenyx Pharmaceutical Inc. stock a top momentum playTake Profit & Risk Adjusted Buy and Sell Alerts - newser.com
Can Ultragenyx Pharmaceutical Inc. rally from current levelsAnalyst Downgrade & Expert Curated Trade Setups - newser.com
Will Ultragenyx Pharmaceutical Inc. stock gain from government policiesPortfolio Performance Report & Reliable Entry Point Trade Alerts - newser.com
Is this a good reentry point in Ultragenyx Pharmaceutical Inc.Weekly Volume Report & Daily Profit Focused Screening - newser.com
Is it too late to sell Ultragenyx Pharmaceutical Inc.IPO Watch & Risk Managed Investment Strategies - newser.com
Ultragenyx Signs $400M Royalty Purchase Agreement - MSN
Campbell & CO Investment Adviser LLC Makes New $309,000 Investment in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
울트라제닉스 파마슈티컬 (RARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.53%
1.88%
자본화:
|
볼륨(24시간):